Biogen vs Denali Therapeutics
BIIB and DNLI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BIIB and DNLI compare
Biogen is the larger company, worth 12 times as much as Denali Therapeutics ($37.0B against $3.0B).
Denali Therapeutics scores higher on the StockData Score (6 against 4 for Biogen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BIIB | DNLI |
|---|---|---|
| Size and price | ||
| Market cap | $37.0B | $3.0B |
| Share price | $250.48 | $18.89 |
| Change, 1 year | 57.0% | 7.5% |
| Change, 5 years | −2.6% | −59.9% |
| Beta (5Y) | 0.50 | 1.66 |
| Employees | 7,500 | 503 |
| StockData Score | ||
| Total score | 4 | 6 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 107× | – |
| P/S | 3.6× | – |
| P/B | – | 3.6× |
| EV/EBITDA | 21.9× | – |
| P/FCF | 17.9× | – |
| FCF yield | 5.6% (better) | −14.5% |
| Fair value | $113.28 | – |
| Margin of safety | −121% | – |
| Growth | ||
| Revenue growth (TTM) | 2.3% | – |
| Revenue growth, 5Y average | −6.0% | – |
| Net income growth (TTM) | −78.4% | – |
| EPS growth (TTM) | −78.7% | – |
| EPS growth, 5Y average | −18.7% | – |
| Profitability | ||
| Gross margin | 74.0% | – |
| Net margin | 3.4% | – |
| FCF margin | 20.1% | – |
| Return on equity | – | −54.9% |
| Return on invested capital | – | −343% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 1.95 | 8.37 (better) |
| Altman Z-score | 3.07 (better) | 1.96 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 96.2% | 97.7% |
| Held by insiders | 0.21% | 6.6% |
| Insider net buying, 12 months | −$905K (better) | −$1.3M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 3.7% | 9.8% |
Go deeper
- BIIB stock overview
- BIIB income statement
- BIIB valuation and score
- DNLI stock overview
- DNLI income statement
- DNLI valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.